Beta-nerve growth factor measurements in mouse serum

Pathobiology of the autophagy-lysosomal pathway in the Huntington's disease brain

Accumulated levels of mutant huntingtin protein (mHTT) and its fragments are considered contributors to the pathogenesis of Huntington's disease (HD). Although lowering mHTT by stimulating autophagy has been considered a possible therapeutic strategy, the role and competence of autophagy-lysosomal pathway (ALP) during HD progression in the human disease remains largely unknown. Here, we used multiplex confocal and ultrastructural immunocytochemical analyses of ALP functional markers in relation to mHTT aggresome pathology in striatum and the less affected cortex of HD brains staged from HD2 to HD4 by Vonsattel neuropathological criteria compared to controls. Immunolabeling revealed the localization of HTT/mHTT in ALP vesicular compartments labeled by autophagy-related adaptor proteins p62/SQSTM1 and ubiquitin, and cathepsin D (CTSD) as well as HTT-positive inclusions. Although comparatively normal at HD2, neurons at later HD stages exhibited progressive enlargement and clustering of CTSD-immunoreactive autolysosomes/lysosomes and, ultrastructurally, autophagic vacuole/lipofuscin granules accumulated progressively, more prominently in striatum than cortex. These changes were accompanied by rises in levels of HTT/mHTT and p62/SQSTM1, particularly their fragments, in striatum but not in the cortex, and by increases of LAMP1 and LAMP2 RNA and LAMP1 protein. Importantly, no blockage in autophagosome formation and autophagosome-lysosome fusion was detected, thus pinpointing autophagy substrate clearance deficits as a basis for autophagic flux declines. The findings collectively suggest that upregulated lysosomal biogenesis and preserved proteolysis maintain autophagic clearance in early-stage HD, but failure at advanced stages contributes to progressive HTT build-up and potential neurotoxicity. These findings support the prospect that ALP stimulation applied at early disease stages, when clearance machinery is fully competent, may have therapeutic benefits in HD patients.

18F-FEAnGA for PET of β-glucuronidase activity in neuroinflammation

Activation of microglia is a hallmark of inflammatory, infectious, and degenerative diseases of the central nervous system. Several studies have indicated that there is an increase in release of β-glucuronidase by activated microglia into the extracellular space at the site of neuroinflammation. β-glucuronidase is involved in the hydrolysis of glycosaminoglycans on the cell surface and the degradation of the extracellular matrix. Therefore, β-glucuronidase might be a biomarker for ongoing neurodegeneration induced by neuroinflammation. In this study, we investigated whether the PET tracer (18)F-FEAnGA was able to detect β-glucuronidase release during neuroinflammation in a rat model of herpes encephalitis.

METHODS

Male Wistar rats were intranasally inoculated with herpes simplex virus 1 (HSV-1) or phosphate-buffered saline as a control. (11)C-(R)-PK11195 and (18)F-FEAnGA small-animal PET scans were acquired for 60 min. Logan graphical analysis was used to calculate (18)F-FEAnGA distribution volumes (DV(Logan)) in various brain areas.

RESULTS

After administration of (18)F-FEAnGA, the area under the activity concentration-versus-time curve of the whole brain was 2 times higher in HSV-1-infected rats than in control rats. In addition, the DV(Logan) of (18)F-FEAnGA was most increased in the frontopolar cortex, frontal cortex, bulbus olfactorius, cerebral cortex, cerebellum, and brainstem of HSV-1-infected rats, when compared with control rats. The conversion of (18)F-FEAnGA to 4-hydroxy-3-nitrobenzyl alcohol was found to be 1.6 times higher in HSV-1-infected rats than in control rats and correlated with the DV(Logan) of (18)F-FEAnGA in the same areas of the brain. Furthermore, the DV(Logan) of (18)F-FEAnGA also correlated with β-glucuronidase activity in the same brain regions. In addition, DV(Logan) of (18)F-FEAnGA showed a tendency to correlate with (11)C-(R)-PK11195 uptake (marker for activated microglia) in the same brain regions.

CONCLUSION

Despite relatively low brain uptake, (18)F-FEAnGA was able to detect an increased release of β-glucuronidase during neuroinflammation.

Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?

Previous reports suggest that age-related lysosomal disturbances contribute to Alzheimer-type accumulations of protein species, blockage of axonal/dendritic transport, and synaptic decline. Here, we tested the hypothesis that lysosomal enzymes are upregulated as a compensatory response to pathogenic protein accumulation. In the hippocampal slice model, tau deposits and amyloidogenic fragments induced by the lysosomal inhibitor chloroquine were accompanied by disrupted microtubule integrity and by corresponding declines in postsynaptic glutamate receptors and the presynaptic marker synaptophysin. In the same slices, cathepsins B, D, and L, beta-glucuronidase, and elastase were upregulated by 70% to 135%. To address whether this selective activation of the lysosomal system represents compensatory signaling, N-Cbz-L-phenylalanyl-L-alanyl-diazomethylketone (PADK) was used to enhance the lysosome response, generating 4- to 8-fold increases in lysosomal enzymes. PADK-mediated lysosomal modulation was stable for weeks while synaptic components remained normal. When PADK and chloroquine were co-infused, chloroquine no longer increased cellular tau levels. To assess pre-existing pathology, chloroquine was applied for 6 days after which its removal resulted in continued degeneration. In contrast, enhancing lysosomal activation by replacing chloroquine after 6 days with PADK led to clearance of accumulated protein species and restored microtubule integrity. Transport processes lost during chloroquine exposure were consequently re-established, resulting in marked recovery of synaptic components. These data indicate that compensatory activation of lysosomes follows protein accumulation events, and that lysosomal modulation represents a novel approach for treating Alzheimer disease and other protein deposition diseases.

Regional CNS uptake of blood-borne nerve growth factor

Nerve growth factor (NGF), in addition to being a neurotrophic substance, has effects on the endocrine and immune systems. For example, intravenous injection of NGF results in a cascade of events leading to an increase in glucocorticoid secretion. While this response appears to be mediated centrally, there has been no evidence that circulating NGF has access to the CNS. Using intravenous injections of 125I-NGF, we find specific uptake at 1 hr but none at 6 hr, into homogenates of the basal forebrain, cerebellum, frontal cortex, hippocampus, and olfactory bulb. By autoradiography, uptake is localized to circumventricular organs, deep layers of the cerebellum, and all layers of the hippocampal region CA1, but not the dentate gyrus. Thus, uptake of blood-borne NGF could affect the hypothalamic-pituitary-adrenal axis via binding to NGF receptors present in the hippocampus. However, the sources of endogenous NGF, the mechanism of access through the blood-brain barrier, the eventual fate of NGF entering from the blood, and the physiological significance of this uptake remain to be elucidated.

Distribution and metabolism patterns of plasma 7S- and beta-NGF in the adult male rat

There is a great deal of controversy on the existence of NGF in body fluids and tissues. To date it remains unknown whether this peptide accumulates preferentially at significant levels in different organs. Thus we undertook the evaluation of kinetic parameters of the disappearance of blood of 125I-7S-NGF and 125I-beta-NGF after intravenous injection in male adult rats. Our results indicate that the plasma half-life of 125I-7S-NGF is approximately twice as long as for 125I-beta-NGF (respectively 61.7 +/- 11.7 min and 36.3 +/- 2.2 min) while the distribution volume is not significantly different between both peptides. Furthermore, the uptake of radioactive NGF by different tissues seems very low as shown by 125I-7S-NGF and 125I-beta-NGF content of the sampled organs compared to the plasma concentration at the same time. These results indicate that the tissue uptake of circulating 7S and beta-NGF is very low in the adult rat. Thus in these animals NGF did not cross the blood-brain barrier and did not accumulate in peripheral organs which are known to contain subsequent amounts of this peptide. This lack of deposition might be due to a binding with plasma proteins (probably alpha 2-macroglobulin).

Natural autoantibodies against the nerve growth factor in autoimmune diseases

High titers of natural autoantibodies against the nerve growth factor (NGF) were detected in the sera of patients with systemic lupus erythematosus, autoimmune thyroiditis and rheumatoid arthritis. Autoantibodies to NGF from these pathological cases displayed higher avidity for NGF and a higher polyreactivity with certain cytoskeletal proteins and with DNA as compared to those from control human subjects. The biological activity, immunoglobulin composition and physiological relevance of these autoantibodies are discussed.

Plasma nerve growth factor access to the postnatal central nervous system

The accessibility of macromolecules to the postnatal mammalian central nervous system is a subject of controversy and importance. One of the biologically important macromolecules in neural development, nerve growth factor (NGF), is thought to be unable to cross the blood-brain barrier in postnatal mammals. In this study, I125 labeled 7S NGF was systemically administered to postnatal rats and was found to accumulate in the brain in significant levels. In addition, brains from saline perfused rats contained intact 7S NGF as determined by gel autoradiography. Radiolabeled NGF was found to be localized to specific areas corresponding to p75 NGF receptor distribution in the hippocampus and cortex by autoradiography. Circulating plasma NGF has access to the developing postnatal neuraxis where it may exert a humoral trophic function.

Developmental changes in nerve growth factor level in rat serum

In serum, nerve growth factor (NGF) forms a complex with alpha 2-macroglobulin (alpha 2M), which formation inhibits the immunoreactivity between NGF and its antibodies. For measuring the serum level of NGF, it is thus necessary to liberate NGF from the NGF-alpha 2M complex and prevent reformation of such complex. The pretreatment of rat serum with 1 M guanidine hydrochloride for a few hours and operation of the enzyme immunoassay (EIA) in the presence of guanidine hydrochloride provided a reliable means for determination of the NGF level in serum. By this procedure we followed the serum NGF level in rats developmentally. It increased from prenatal day 2 to postnatal day 5 and decreased slightly at postnatal week 3, thereafter remaining constant throughout adulthood. In pregnant rats, the NGF level in serum increased threefold to fivefold before birth and then decreased rapidly. These data suggest that serum NGF level may reflect the demand for this molecule during establishment of the peripheral nervous system.

Low serum levels of nerve growth factor in diabetic neuropathy

Several structural and functional similarities between nerve growth factor and insulin have been described. Diabetes mellitus, a disease with absolute or relative deficiency of insulin is frequently associated with peripheral neuropathy whose physiopathological mechanisms are obscure. In this study, we measured serum levels of NGF in 18 patients with diabetic neuropathy and 9 healthy controls; patients with diabetic neuropathy had lower levels of NGF than controls (p less than 0.01). When patients were separated in two groups according to degree of impairment of motor nerve conduction velocity, those with more than 10% of impairment, had lower levels of NGF than those with less than 10% of impairment, or controls. It was found a correlation between NGF levels and decrease of motor nerve conduction velocity; then, diabetic neuropathy seems to be associated to low serum levels of NGF, pointing out a possible role of NGF in the pathology of diabetic neuropathy.

Biological demonstration of nerve growth factor in the rat pituitary gland

Explants of anterior, intermediate and posterior pituitary lobes of rats at various ages evoked an intense nerve fibre outgrowth when co-cultured with neonatal sympathetic superior cervical ganglia in a collagen gel medium. Freezing and thawing of pituitary lobes, prior to culture, did not abolish their growth-promoting effect. Since the addition of antiserum to nerve growth factor in the culture medium inhibited totally the stimulative action of both fresh and frozen pituitary explants it is suggested that the stimulation is mediated by nerve growth factor or an immunologically related molecule. Based on the present results it is concluded that nerve growth factor is synthesized by both the anterior, intermediate and posterior lobes throughout the postnatal period, as well as in adult rats. The function of nerve growth factor in the pituitary gland is discussed.

Nerve growth factor-like activity in the rat pituitary intermediate lobe

Nerve growth factor (NGF)-like immunoreactivity was demonstrated in the rat pituitary intermediate lobe by indirect immunofluorescence method using antisera specific to beta-NGF isolated from adult male mouse submaxillary salivary gland. Co-culture of frozen or fresh intermediate lobes with newborn rat superior cervical ganglion resulted in marked fiber growth from the ganglion, which was totally inhibited by NGF antiserum, suggesting the presence in situ and secretion in vitro of biologically active pituitary NGF. Pituitary stalk transection caused decrease in both the NGF immunoreactivity and biological activity. These findings suggest that pituitary NGF level is under neural regulation.

Molecular forms of nerve growth factor in mouse submaxillary glands

By use of immunoblot analysis, we demonstrate the presence of a nerve growth factor with a relative molecular mass (Mr) of 53,000 in submaxillary glands of adult male and female mice in addition to the 13,000 form previously discovered in this tissue. Both the Mr 53,000 and 13,000 forms of nerve growth factor are present at equal concentrations in salivary glands of male mice while the Mr 53,000 form is present at a greater concentration than the Mr 13,000 form in the glands of female mice. Testosterone pretreatment, however, specifically augments the Mr 13,000 form of nerve growth factor in the salivary glands of female mice. The existence of nerve growth factor with molecular weight of 53,000, which is higher than the molecular size predicted for the two precursor forms of nerve growth factor, suggest the possibility that one of the nerve growth factor precursors or a product derived from it may undergo post-translational modification in submaxillary glands of mice.

Mouse saliva prevents the beta-nerve growth factor-dependent neurite formation in PC-12 cells

A highly sensitive and specific competitive beta-nerve growth factor radioimmunoassay (beta NGF-RIA) was utilized to determine the beta NGF levels in epinephrine-provoked saliva of adult male and female Swiss-Webster mice. Saliva beta NGF levels in males were higher than in females. In order to assess the immunoreactive material measured in the RIA as biologically active beta NGF, saliva of male and female mice was examined for the neurite outgrowth responsiveness both in the rat pheochromocytoma tumor cell line (PC-12) and 8-day-old chick embryo dorsal root sensory ganglion (DRG) bioassay systems. At concentrations (based on the RIA values) sufficient to saturate both high and low affinity beta NGF-receptors (100 ng and above), saliva of both male and female mice did not elicit neurite outgrowth in the PC-12 bioassay system. In contrast, similar concentrations of saliva stimulated extensive neurites in the DRG bioassay system. When serum of aggression-provoked male mice (which also contained high serum beta NGF levels as indicated by the RIA) was tested, both the PC-12 and DRG bioassay systems readily responded with neurite extension. In the PC-12 bioassay system, saliva of both sexes stimulated cell proliferation and cell aggregation, but not cell substratum-adhesion. Addition of saliva also prevented the cell substratum adhesion and the formation of neurites induced by purified submandibular gland (SMG)-beta NGF. Epidermal growth factor (EGF), a potent mitogen present in mouse saliva, did not prevent the neurite outgrowth induced by the purified SMG-beta NGF. In summary, the results suggest that saliva of adult male and female mice may contain biologically interfering substances for beta NGF-dependent neurite formation in the PC-12 bioassay system.